26,361 Shares in LifeMD, Inc. $LFMD Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,361 shares of the company’s stock, valued at approximately $359,000. Campbell & CO Investment Adviser LLC owned approximately 0.06% of LifeMD as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of LifeMD in the 1st quarter worth about $1,545,000. Jump Financial LLC raised its position in LifeMD by 69.9% during the first quarter. Jump Financial LLC now owns 168,881 shares of the company’s stock worth $919,000 after acquiring an additional 69,502 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of LifeMD in the second quarter valued at about $818,000. Quantbot Technologies LP lifted its holdings in shares of LifeMD by 467.6% in the first quarter. Quantbot Technologies LP now owns 68,006 shares of the company’s stock valued at $370,000 after purchasing an additional 56,024 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of LifeMD by 5.4% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock valued at $5,342,000 after purchasing an additional 50,600 shares during the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Stock Up 0.2%

Shares of LFMD opened at $4.63 on Monday. LifeMD, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $15.84. The company’s fifty day moving average is $6.07 and its two-hundred day moving average is $8.73. The firm has a market cap of $219.55 million, a PE ratio of -22.05 and a beta of 1.57. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the sale, the insider owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LFMD shares. Lake Street Capital cut their price objective on LifeMD from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. HC Wainwright reduced their price objective on LifeMD from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Wall Street Zen downgraded shares of LifeMD from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, KeyCorp cut their price objective on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $13.17.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.